ClinicalTrials.gg
CompletedNCT01557504Updated Oct 28, 2020Results posted

A Study to Assess the Pharmacokinetics and the Ability for Pediatric Participants With Type 2 Diabetes to Swallow MK-0431A XR Tablets (MK-0431A-296)

A Phase 1 interventional study of Sitagliptin/metformin XR and Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-10-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
155th of 197
25 · median 102
Started
2012
with 15 others
Phase 1
23 of 198
none open now
Registered
114th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 155th largest by enrollment of the 197 interventional ones that give a count, is one of 16 that started in 2012, is one of 23 in phase 1, and was the 114th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess:

  1. the safety and tolerability of two sitagliptin 50 mg/metformin 1000 mg XR tablets in pediatric participants with type 2 diabetes mellitus (T2DM), aged 10 to 17 years
  2. the ability of pediatric participants with T2DM, aged 10 to 17 years, to swallow two sitagliptin 50 mg/metformin 1000 mg XR tablets or two matching placebo tablets (excluding marking)
  3. the pharmacokinetics of sitagliptin and metformin following the administration of two sitagliptin 50 mg/metformin 1000 mg XR tablets to pediatric participants with T2DM, aged 10 to 17 years.
03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participant of must not be pregnant and agrees to use (and/or have their partner use) two acceptable methods of
  • T2DM diagnosed by American Diabetes Association criteria
  • No abnormality on
  • No clinical or laboratory evidence to indicate a diagnosis of type 1 diabetes
  • Nonsmoker

Exclusion criteria

Exclusion Criteria:

  • Mental or legal incapacitation
  • Estimated of 80 mL/min or lower
  • History of stroke, chronic seizures, or major neurological disorder
  • History of endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
  • History of neoplastic disease
  • Unable to refrain from or anticipates the use of any medication (with the exception of metformin and thyroid hormone) from approximately 2 weeks before the first dose of study drug through the poststudy visit
  • Consumes alcohol or consumes excessive amounts of coffee, tea, cola, or other caffeinated beverages
  • Had surgery, donated or lost 1 unit of blood, or participated in another study within the past 4 weeks
  • History of multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
  • Currently a regular user (including illicit drugs) or has a history of drug (including alcohol) abuse
  • Lactose intolerant
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Sitagliptin/metformin XR followed by placebo

    Day 1 (Period 1): participants will receive a single dose of two sitagliptin/metformin XR tablets with a low- to moderate-fat meal (breakfast). Days 2-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.

    Drug: Sitagliptin/metformin XR · Drug: Placebo · Drug: Metformin · Drug: Thyroid hormone

  • Placebo comparator
    Placebo only

    Days 1-4 (Period 1): participants will receive a single dose of two matching placebo tablets. Days 5-9 (Period 2): participants will receive a single dose of two matching placebo tablets with the evening meal.

    Drug: Placebo · Drug: Metformin · Drug: Thyroid hormone

Interventions

  • DrugSitagliptin/metformin XR

    Drug pages: Sitagliptin · Metformin

    Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metformin XR 2000 mg).

    Also known as: MK-0431A XR, Janumet XR

  • DrugPlacebo

    Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.

  • Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.

  • DrugThyroid hormone

    Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2

    The Swallowing Ability Questionnaire was completed on Day 2 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

    Time frame: Day 2

  2. Number of Participants Who Successfully Swallowed Study Med on Day 4

    The Swallowing Ability Questionnaire was completed on Day 4 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

    Time frame: Day 4

  3. Number of Participants Who Successfully Swallowed Study Med on Day 6

    The Swallowing Ability Questionnaire was completed on Day 6 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

    Time frame: Day 6

  4. Number of Participants Who Successfully Swallowed Study Med on Day 9

    The Swallowing Ability Questionnaire was completed on Day 9 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

    Time frame: Day 9

  5. Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

    In this study, metformin products were withheld 24 hours (hrs) prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hrs post study drug administration. Owing to resumption of therapeutic metformin administration 24 hrs after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and area under the curve 0 to 24 hrs (AUC0-24hr). Therefore, metformin arm is not included in this endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

  6. AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

    Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose

  7. AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR

    In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose

  8. Area Under the Curve 0 to Infinity (AUC 0-∞) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

    In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

  9. Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR

    Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

  10. Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR

    In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

  11. Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR

    In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

  12. Apparent Terminal Half Life (t1/2) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR

    In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.

    Time frame: Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose

  13. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.

    Time frame: Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)

  14. Number of Participants Who Experienced an Abnormal Vital Sign Value

    Vital sign measurements included blood pressure, heart rate, respiratory rate, and oral temperature.

    Time frame: Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)

  15. Number of Participants Who Discontinued Study Drug Due to an AE

    An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.

    Time frame: Up to 9 days

07

Results

Posted May 22, 2015

Participant flow

Participant flow — Overall Study
MilestoneSitagliptin/Metformin XR Followed by PlaceboPlacebo
Started1312
Completed1212
Not completed10
Withdrew: Physician decision10

Outcome measures

PrimaryNumber of Participants Who Successfully Swallowed Study Medication (Med) on Day 2

The Swallowing Ability Questionnaire was completed on Day 2 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

Time frame:
Day 2
Reported as:
Number · Participants
Number of Participants Who Successfully Swallowed Study Medication (Med) on Day 2
ParticipantsAll Treated Participants
Strongly Agreed: Could Only Swallow Med With Help6
Agreed: Could Only Swallow Med With Help7
Strongly Agreed: Easy to Start Swallowing Med10
Agreed: Easy to Start Swallowing Med12
Strongly Agreed: Easy to Swallow Med13
Agreed: Easy to Swallow Med10
Strongly Agreed: Felt Like Med Got Stuck in Throat0
Agreed: Felt Like Med Got Stuck in Throat4
Strongly Agreed: Had to Swallow Med More Than Once2
Agreed: Had to Swallow Med More Than Once3
PrimaryNumber of Participants Who Successfully Swallowed Study Med on Day 4

The Swallowing Ability Questionnaire was completed on Day 4 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

Time frame:
Day 4
Reported as:
Number · Participants
Number of Participants Who Successfully Swallowed Study Med on Day 4
ParticipantsAll Treated Participants
Strongly Agreed: Could Only Swallow Med With Help6
Agreed: Could Only Swallow Med With Help6
Strongly Agreed: Easy to Start Swallowing Med8
Agreed: Easy to Start Swallowing Med14
Strongly Agreed: Easy to Swallow Med8
Agreed: Easy to Swallow Med15
Strongly Agreed: Felt Like Med Got Stuck in Throat0
Agreed: Felt Like Med Got Stuck in Throat4
Strongly Agreed: Had to Swallow Med More Than Once0
Agreed: Had to Swallow Med More Than Once5
PrimaryNumber of Participants Who Successfully Swallowed Study Med on Day 6

The Swallowing Ability Questionnaire was completed on Day 6 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

Time frame:
Day 6
Reported as:
Number · Participants
Number of Participants Who Successfully Swallowed Study Med on Day 6
ParticipantsAll Treated Participants
Strongly Agreed: Could Only Swallow Med With Help5
Agreed: Could Only Swallow Med With Help7
Strongly Agreed: Easy to Start Swallowing Med10
Agreed: Easy to Start Swallowing Med11
Strongly Agreed: Easy to Swallow Med11
Agreed: Easy to Swallow Med12
Strongly Agreed: Felt Like Med Got Stuck in Throat0
Agreed: Felt Like Med Got Stuck in Throat3
Strongly Agreed: Had to Swallow Med More Than Once2
Agreed: Had to Swallow Med More Than Once5
PrimaryNumber of Participants Who Successfully Swallowed Study Med on Day 9

The Swallowing Ability Questionnaire was completed on Day 9 after the participant received two matching placebo tablets (excluding marking) following consumption of a low- to moderate-fat meal in pediatric participants aged 10 to 17 years. The questionnaire consisted of five parts: could only swallow study med with help, easy to start swallowing study med, easy to swallow study med, felt like study med got stuck in throat, and had to swallow study med more than once. The number of participants who strongly agreed or agreed in each of the five parts is reported.

Time frame:
Day 9
Reported as:
Number · Participants
Number of Participants Who Successfully Swallowed Study Med on Day 9
ParticipantsAll Treated Participants
Strongly Agreed: Could Only Swallow Med With Help9
Agreed: Could Only Swallow Med With Help5
Strongly Agreed: Easy to Start Swallowing Med9
Agreed: Easy to Start Swallowing Med13
Strongly Agreed: Easy to Swallow Med12
Agreed: Easy to Swallow Med11
Strongly Agreed: Felt Like Med Got Stuck in Throat1
Agreed: Felt Like Med Got Stuck in Throat1
Strongly Agreed: Had to Swallow Med More Than Once2
Agreed: Had to Swallow Med More Than Once5
PrimaryArea Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

In this study, metformin products were withheld 24 hours (hrs) prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hrs post study drug administration. Owing to resumption of therapeutic metformin administration 24 hrs after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to maximum plasma concentration (Cmax), time to maximum plasma concentration (Tmax) and area under the curve 0 to 24 hrs (AUC0-24hr). Therefore, metformin arm is not included in this endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · nM*hr/mL
Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR
nM*hr/mLSitagliptin
Area Under the Curve 0 to Last (AUC 0-last) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR5940 ± 25.7
PrimaryAUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose
Reported as:
Geometric mean · nM*hr
AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR
nM*hrSitagliptin
AUC 0-24 of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR5310 ± 22.4
PrimaryAUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR

In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, and 24 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR
ng*hr/mLMetformin
AUC 0-24 of Metformin Following Single Administration of Sitagliptin/Metformin XR14200 ± 39.7
PrimaryArea Under the Curve 0 to Infinity (AUC 0-∞) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR

In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · nM*hr
Area Under the Curve 0 to Infinity (AUC 0-∞) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR
nM*hrSitagliptin
Area Under the Curve 0 to Infinity (AUC 0-∞) of Sitagliptin Following Single Administration of Sitagliptin/Metformin XR6020 ± 24.8
PrimaryCmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR

Due different units of measure for sitagliptin and metformin, metformin data are presented in another endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · nM
Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR
nMSitagliptin
Cmax of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR757 ± 40.1
PrimaryCmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR

In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Due different units of measure for sitagliptin and metformin, sitagliptin data are presented in another endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · ng/mL
Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR
ng/mLMetformin
Cmax of Metformin Following Single Dose Administration of Sitagliptin/Metformin XR1490 ± 29.1
PrimaryTmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR

In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Reported as:
Median · Hour
Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR
HourSitagliptinMetformin
Tmax of Sitagliptin and Metformin Following Single Dose Administration of Sitagliptin/Metformin XR1.52 (0.97 to 3.05)5.00 (3.98 to 7.22)
PrimaryApparent Terminal Half Life (t1/2) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR

In this study, metformin products were withheld 24 hours prior to sitagliptin/metformin XR administration and were permitted to re-initiate 24 hours post study drug administration. Owing to resumption of therapeutic metformin administration 24 hours after sitagliptin/metformin XR administration for all participants, metformin pharmacokinetic analyses were restricted to Cmax, Tmax and AUC0-24hr. Therefore, metformin arm is not included in this endpoint.

Time frame:
Pre-dose, and 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48, and 72 hours post-dose
Reported as:
Geometric mean · Hour
Apparent Terminal Half Life (t1/2) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR
HourSitagliptin
Apparent Terminal Half Life (t1/2) of Sitagliptin Following Single Dose Administration of Sitagliptin/Metformin XR10.0 ± 27.3
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.

Time frame:
Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsSitagliptinPlacebo
Number of Participants Who Experienced an Adverse Event (AE)55
PrimaryNumber of Participants Who Experienced an Abnormal Vital Sign Value

Vital sign measurements included blood pressure, heart rate, respiratory rate, and oral temperature.

Time frame:
Up to 23 days (including approximately 10 to 14 days after the last dose of study drug)
Reported as:
Number · Participants
Number of Participants Who Experienced an Abnormal Vital Sign Value
ParticipantsSitagliptinPlacebo
Number of Participants Who Experienced an Abnormal Vital Sign Value00
PrimaryNumber of Participants Who Discontinued Study Drug Due to an AE

An AE was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an IMP, regardless of causal relationship and even if no IMP has been administered.

Time frame:
Up to 9 days
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an AE
ParticipantsSitagliptinPlacebo
Number of Participants Who Discontinued Study Drug Due to an AE00

Adverse events

Collected over Up to 23 days (including approximately 10 to 14 days after the last dose of study drug). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin/Metformin XR Followed by Placebo—0/13 (0%)5/13 (38.5%)
Placebo—0/12 (0%)5/12 (41.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventSitagliptin/Metformin XR Followed by PlaceboPlacebo
NasopharyngitisInfections and infestations1/131/12
Upper respiratory tract infectionInfections and infestations0/131/12
ArthralgiaMusculoskeletal and connective tissue disorders0/131/12
Plantar fasciitisMusculoskeletal and connective tissue disorders0/131/12
Vulvovaginal pruritusReproductive system and breast disorders0/131/12
DiarrhoeaGastrointestinal disorders1/130/12
VomitingGastrointestinal disorders1/130/12
Seasonal allergyImmune system disorders1/130/12
Urine analysis abnormalInvestigations1/130/12
HypoglycaemiaMetabolism and nutrition disorders1/130/12

Baseline characteristics

Age, Customized
Age, Customized(Participants)Sitagliptin/Metformin XR Followed by PlaceboPlaceboTotal
10-13 years437
14-17 years9918
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin/Metformin XR Followed by PlaceboPlaceboTotal
Female9817
Male448
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Apr 2014, 21 months.

Results were first posted in May 2015, 1 year after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 21 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2012
First posted
Mar 19, 2012
StartActual
Jul 18, 2012
Primary completionActual
Apr 29, 2014
CompletionActual
Apr 29, 2014
Results first posted
May 22, 2015
Last update
Oct 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01557504
Responsible party
Sponsor
First posted
Mar 19, 2012
Start date
Jul 18, 2012
Primary completion
Apr 29, 2014
Completion
Apr 29, 2014
Results posted
May 22, 2015
Last update
Oct 28, 2020

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion